I-MAB SPONS.ADS/1 -0001 (0VY) - Total Liabilities
Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) has total liabilities worth €29.58 Million EUR (≈ $34.58 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 0VY operating cash flow to assess how effectively this company generates cash.
I-MAB SPONS.ADS/1 -0001 - Total Liabilities Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's total liabilities have evolved over time, based on quarterly financial data. Check 0VY asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
I-MAB SPONS.ADS/1 -0001 Competitors by Total Liabilities
The table below lists competitors of I-MAB SPONS.ADS/1 -0001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KIP Real Estate Investment Trust
KLSE:5280
|
Malaysia | RM727.93 Million |
|
Aviat Networks Inc
NASDAQ:AVNW
|
USA | $344.77 Million |
|
Excelliance MOS
TWO:5299
|
Taiwan | NT$753.56 Million |
|
Acsion Ltd
JSE:ACS
|
South Africa | ZAC4.76 Billion |
|
Aurona Industries
TWO:8074
|
Taiwan | NT$1.63 Billion |
|
Value Added Technology Co. Ltd
KQ:043150
|
Korea | ₩170.42 Billion |
|
Pan Malaysia Holdings Bhd
KLSE:1287
|
Malaysia | RM156.57 Million |
|
Kingstone Companies Inc
NASDAQ:KINS
|
USA | $350.83 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down I-MAB SPONS.ADS/1 -0001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see I-MAB SPONS.ADS/1 -0001 market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how I-MAB SPONS.ADS/1 -0001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual total liabilities of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €29.58 Million ≈ $34.58 Million |
+156.78% |
| 2024-12-31 | €11.52 Million ≈ $13.47 Million |
-90.88% |
| 2023-12-31 | €126.34 Million ≈ $147.70 Million |
-25.10% |
| 2022-12-31 | €168.68 Million ≈ $197.20 Million |
+3.22% |
| 2021-12-31 | €163.42 Million ≈ $191.05 Million |
-- |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more